Halozyme Therapeutics Inc (HALO)

Net profit margin

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Net income (ttm)	US$ in thousands	444,091	392,467	337,293	318,802	281,594	253,908	233,705	181,636	202,129	211,197	366,150	434,923	402,710	409,104	228,724	163,083	129,085	21,524	-39,698	-80,139
Revenue (ttm)	US$ in thousands	1,015,324	947,355	873,304	862,989	829,253	780,710	773,653	704,980	660,116	580,623	487,477	471,567	443,310	463,010	412,496	331,262	267,594	199,556	180,470	164,397
Net profit margin		43.74%	41.43%	38.62%	36.94%	33.96%	32.52%	30.21%	25.76%	30.62%	36.37%	75.11%	92.23%	90.84%	88.36%	55.45%	49.23%	48.24%	10.79%	-22.00%	-48.75%

December 31, 2024 calculation

Net profit margin = Net income (ttm) ÷ Revenue (ttm)
= $444,091K ÷ $1,015,324K
= 43.74%

Halozyme Therapeutics Inc's net profit margin has shown significant fluctuations over the periods outlined. The net profit margin measures the percentage of revenue that translates into profit after all expenses have been deducted.

Between March 31, 2020, and December 31, 2021, the company experienced a positive trend in net profit margin, moving from negative figures to above 48%. This indicates an improvement in the company's profitability during this period.

The net profit margin continued to increase steadily through March 31, 2022, reaching its peak at 92.23%. This surge suggests effective cost management and revenue generation strategies implemented by the company.

However, starting from June 30, 2022, the net profit margin began to decrease, showing a decline to 30.21% by the end of June 30, 2023. This decline could result from increased expenses or lower revenue during this period.

Subsequently, the net profit margin showed a slight recovery by December 31, 2024, reaching 43.74%. Although the margin had dropped from its peak in 2022, the company was able to maintain a reasonable level of profitability.

Overall, the analysis indicates fluctuations in Halozyme Therapeutics Inc's net profit margin over the periods provided, with both positive and negative growth trends observed. Continuous monitoring and evaluation of the company's financial performance will be crucial for investors and stakeholders to assess its long-term sustainability and profitability.